ARS Pharmaceuticals heads into its third-quarter report with an unusual split personality. Wall Street is asking for a sharply narrower loss and a big jump in sales in the very quarter when the company's new leadership began dismantling the costly consumer marketing machine that was supposed to drive neffy's growth. The stock has already voted on how that pivot looks: shares have fallen 28.4% since the last report and now sit at $3.65, essentially on the $3.64 low of the post-earnings range and less than half the 200-day moving average of $7.49. That leaves the report as a referendum on whether the new strategy can deliver growth that is both leaner and still visible.

The consensus calls for a loss of $0.34 per share, versus $0.63 last quarter and $0.52 a year ago, on revenue of $42.7 million. That revenue figure implies roughly 31% growth from the year-ago $32.5 million and a sequential step-up of about 27% from the $33.7 million reported in the second quarter. The loss improvement is the more believable half of the equation. Management guided combined cash SG&A and R&D for the second half to $100 million to $110 million, which amounts to a cut of more than 40% in cash selling costs compared with the first half. If that discipline shows up on schedule, the bottom line should improve almost mechanically, so a narrower loss alone will not say much about the health of the business.

The revenue line is where the real test lies. US net product revenue was $26.2 million last quarter, a recovery from the seasonally weak first quarter but still below the $31.3 million peak reached a year earlier. The Street now appears to be betting that a fully deployed sales force of roughly 150 reps can push sales meaningfully higher even as broad consumer advertising is replaced with cheaper social and search campaigns. Management's evidence for that bet is genuine: total US share doubled to 5%, share in rep-targeted territories reached 8% against about 1% where reps do not call, and unique prescribers topped 16,000. Continued gains in share and prescriber breadth, translated into product revenue clearly above the prior peak, would validate the idea that provider-focused selling can carry the brand. Flat or declining product sales despite rising share would suggest the market itself is growing too slowly for the leaner model to work.

Several secondary issues could color the reaction. Gross margin slipped to 62% on reserves for short-dated product and manufacturing inefficiencies, so a rebound would signal those were temporary rather than structural. Cash fell to $143.8 million from $288 million a year earlier, and the newly articulated path to cash-flow breakeven by the end of 2027 depends on the burn rate actually bending this quarter. Any update on payer access also matters. The CVS Caremark formulary win that dominated earlier calls was quietly reframed last quarter as necessary but insufficient, and silence on it again would reinforce the sense that a once-central catalyst has faded. The chronic urticaria readout has already slipped to early 2027, and the July license tied to a possible neffy line extension remains optionality rather than a near-term driver.

Sentiment has improved noticeably, with the bullish reading climbing to 0.47 from 0.25 heading into the prior report, even as the share price slid. That disconnect suggests some investors view the reset and cost cuts as a floor-building exercise, though a stock pinned at its lows shows the market has not yet bought in.

Ultimately, this report hinges on one question: can share gains convert into product revenue growth fast enough to justify a consensus that already assumes a strong sequential jump, while spending falls sharply? A clean beat on both lines would recast the pivot as disciplined growth. A narrower loss built only on cost cuts, paired with soft sales, would confirm the fear that ARS is shrinking its way toward breakeven.